# Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

> clinical trial · VERIFIED · 2026-09-02

Status: COMPLETED · Sponsor: BeiGene · Condition: Breast Cancer

- Company: BeiGene
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04276493

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.